01—Abstract
Summary
Summary of the 8-K filed July 3, 2024. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. disclosed in this Form 8-K, filed July 3, 2024 under Item 5.02, that director Ashley M.
Keating resigned from the Board of Directors effective June 30, 2024. The filing states her resignation did not result from any disagreement with the Company on matters relating to its operations, policies or practices. The Board, following a recommendation from its independent directors, unanimously elected Dr. Dani S.
Zander to fill the resulting Class III director vacancy, effective July 1, 2024, with her term running until the 2025 Annual Meeting of Stockholders. Dr. Zander was also appointed to the Nominating and Governance Committee effective the same date. She is the MacKenzie Chair of the Department of Pathology and Laboratory Medicine at the University of Cincinnati and Chief of Pathology and Laboratory Medicine for UC Health, and the filing describes her background in lung pathology, cytopathology and academic pathology leadership.
Under the Company's standard non-employee director compensation program, Dr. Zander received on July 1, 2024 an option to purchase 824 shares of common stock at an exercise price equal to that day's closing price, with a seven-year term. The Company also entered into its standard director and officer indemnification agreement with her.
02—Key points
Key Highlights
- Director Ashley M. Keating resigned from the Board effective June 30, 2024, with no disagreement with the Company cited as a reason.
- Dr. Dani S. Zander was elected as a Class III director effective July 1, 2024, filling the vacancy, and serves until the 2025 Annual Meeting of Stockholders.
- Dr. Zander was appointed to the Nominating and Governance Committee effective July 1, 2024.
- Dr. Zander is MacKenzie Chair of Pathology and Laboratory Medicine at the University of Cincinnati and Chief of Pathology and Laboratory Medicine for UC Health.
- Dr. Zander received an option to purchase 824 shares of common stock on July 1, 2024, at the closing price that day, with a seven-year term.
- The Company entered into its standard director and officer indemnification agreement with Dr. Zander.
- The filing contains no financial results; the disclosure concerns board composition and director compensation only.
03—Questions
Frequently Asked Questions
Why did Ashley M. Keating leave the Board?
She notified the Company on June 28, 2024 of her resignation, effective June 30, 2024. The filing states it did not result from any disagreement with the Company on operations, policies or practices.
Who replaced Ms. Keating and in what role?
The Board elected Dr. Dani S. Zander as a Class III director effective July 1, 2024, to fill the vacancy. She also joined the Nominating and Governance Committee on the same date.
How long will Dr. Zander serve on the Board?
She holds the Class III director seat until the 2025 Annual Meeting of Stockholders, or until her successor is elected and qualified, or until her earlier death, resignation or removal.
How will Dr. Zander be compensated?
She participates in the Company's standard non-employee director compensation program. On July 1, 2024 she received an option to buy 824 shares at the July 1, 2024 closing price, with a seven-year term.
What is Dr. Zander's professional background?
The filing describes her as a practicing lung pathologist and cytopathologist whose research focuses on lung cancer and lung transplantation. She is immediate past president of the Association of Pathology Chairs, now the Association for Academic Pathology, and holds a B.A. from New York University and an M.D. from the University of Florida.
04—Continue